glp 1 access Who Gets the Shot? GLP-1 by State Novo Nordisk Expands GLP-1 Access

In 2023, Pfizer terminated the clinical development of two oral GLP-1 small molecule agonists, Lotiglipron and Danuglipron

has synthesized glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes and hyperglycemia

Making sustainable adjustments to your daily routine helps lower the chances of regaining weight and ensures you get the most out of GLP-1 treatments, leading to steadier and more enduring progress

Emotional eating is another hurdle

Changes in mental health GLP-1s and other incretin medications can have a range of effects on a persons mental and emotional well-being

At 72 weeks, 42.7% of GLP-1 receptor agonist users lost any amount of weight, and 10.5% lost 10% or more of their body weight